Developing RNA treatments for Huntington’s disease
Advancing RNA Therapeutics for Huntington’s Disease
['FUNDING_U01'] · UNIV OF MASSACHUSETTS MED SCH WORCESTER · NIH-10784710
This study is testing a new treatment that uses special RNA to lower the harmful protein linked to Huntington’s disease, and it’s designed for people with this condition to help improve their brain health.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF MASSACHUSETTS MED SCH WORCESTER (nih funded) |
| Locations | 1 site (WORCESTER, UNITED STATES) |
| Trial ID | NIH-10784710 on ClinicalTrials.gov |
What this research studies
This research focuses on creating advanced RNA therapies to lower the levels of mutant huntingtin protein in the brain, which is responsible for Huntington’s disease. By using modified, di-branched siRNA, the team aims to invoke RNA interference to reduce the harmful protein levels effectively. The treatment is designed to be administered once into the cerebrospinal fluid, with the goal of achieving long-term effects throughout the brain. This innovative approach could not only help patients with Huntington’s disease but may also be applicable to other similar neurological disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Huntington’s disease, particularly those in the early to mid-stages of the condition.
Not a fit: Patients with late-stage Huntington’s disease or those with other unrelated neurological disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that significantly slows the progression of Huntington’s disease and improves patients' quality of life.
How similar studies have performed: Other research has shown promise in using RNA interference for similar neurological conditions, indicating a potential for success with this approach.
Where this research is happening
WORCESTER, UNITED STATES
- UNIV OF MASSACHUSETTS MED SCH WORCESTER — WORCESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ARONIN, NEIL — UNIV OF MASSACHUSETTS MED SCH WORCESTER
- Study coordinator: ARONIN, NEIL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Amyotrophic Lateral Sclerosis Motor Neuron Disease, Gehrig's Disease, Lou Gehrig Disease